Nomura Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nomura Holdings’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$629K	–	2004
2026 Q1	$629K	Buy	+30,000	New	+$676K	﹤0.01%	1298
2025 Q3	–	Sell	-5,742	Closed	-$172K	–	2043
2025 Q2	$209K	Buy	+5,742	New	+$207K	﹤0.01%	1294
2023 Q2	–	Sell	-329,170	Closed	-$13.2M	–	1584
2023 Q1	$13.2M	Buy	329,170 +101,182	+44%	+$4.34M	0.04%	289
2022 Q4	$10.6M	Buy	227,988 +157,915	+225%	+$6.21M	0.04%	299
2022 Q3	$2.9M	Sell	70,073 -7,939	-10%	-$408K	0.01%	718
2022 Q2	$4.89M	Buy	+78,012	New	+$4.8M	0.02%	566
2020 Q1	–	Sell	-6,574	Closed	-$282K	–	1179
2019 Q4	$282K	Buy	+6,574	New	+$271K	﹤0.01%	978

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Nomura Holdings's RARE Position: Q2 2026 in Review

Nomura Holdings sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 30,000 shares — an estimated $629K sold.

Nomura Holdings first reported a position in RARE in Q4 2019 and held it in 7 quarters. The position peaked at $13.2M in Q1 2023. 287 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Nomura Holdings reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 30,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $629K.
Nomura Holdings first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 7 quarters.
Nomura Holdings's Ultragenyx Pharmaceutical position peaked at $13.2M in Q1 2023.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.